The Food and Drug Administration last week approved lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) for adults and adolescents weighing at least 35 kg. The product is the first twice-a-year PrEP option available in the United States, according to a press release from manufacturer Gilead. It offers an advantage over daily oral PrEP because it requires less frequent dosing, which could lead to better adherence. Clinical trials published in The New …
Read More